Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

481 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J, Sandström M, Wester K, Tolmachev V, Orlova A. Malmberg J, et al. Nucl Med Biol. 2011 Nov;38(8):1093-102. doi: 10.1016/j.nucmedbio.2011.04.005. Epub 2011 Jun 22. Nucl Med Biol. 2011. PMID: 22137850
In this study, we evaluated whether ABY-025 Affibody molecule, a small (∼ 7-kDa) HER2-binding scaffold protein, produces superior tumor-to-nontumor ratios compared with those obtained through the use of radiolabeled humanized anti-HER2 antibody, trastuzumab. ...Trastuzumab …
In this study, we evaluated whether ABY-025 Affibody molecule, a small (∼ 7-kDa) HER2-binding scaffold protein, produces superior tum …
Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution.
Tolmachev V, Koziorowski J, Sivaev I, Lundqvist H, Carlsson J, Orlova A, Gedda L, Olsson P, Sjöberg S, Sundin A. Tolmachev V, et al. Bioconjug Chem. 1999 May-Jun;10(3):338-45. doi: 10.1021/bc980033s. Bioconjug Chem. 1999. PMID: 10346862
Mercapto-undecahydro-closo-dodecaborate(2-) (BSH) was reacted with the double bond of allyldextran to form a boronated dextran compound of the molecular size of about 70 kDa. ...The degradation rate, as indicated by thyroid uptake, was found low. [125I]Iodo-closo-dodecabor …
Mercapto-undecahydro-closo-dodecaborate(2-) (BSH) was reacted with the double bond of allyldextran to form a boronated dextran compou …
Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET.
Höglund J, Tolmachev V, Orlova A, Lundqvist H, Sundin A. Höglund J, et al. Nucl Med Biol. 2000 Nov;27(8):837-43. doi: 10.1016/s0969-8051(00)00153-0. Nucl Med Biol. 2000. PMID: 11150718
Optimization of the labeling conditions and further conjugation gave a total yield ( mean+/-max error) of 49+/-2%. The immunoreactivity of the antibodies was retained after labeling. ...
Optimization of the labeling conditions and further conjugation gave a total yield ( mean+/-max error) of 49+/-2%. The immunoreactivi …
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry.
Orlova A, Höglund J, Lubberink M, Lebeda O, Gedda L, Lundqvist H, Tolmachev V, Sundin A. Orlova A, et al. Cancer Biother Radiopharm. 2002 Aug;17(4):385-96. doi: 10.1089/108497802760363187. Cancer Biother Radiopharm. 2002. PMID: 12396703
The absorbed doses in stomach, spleen and thyroid were underestimated by a factor 2-3. Positron-emitting analogues can be used to predict the astatine-derived dose in critical organs. ...
The absorbed doses in stomach, spleen and thyroid were underestimated by a factor 2-3. Positron-emitting analogues can be used to pre …
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, Tolmachev V, Carlsson J. Sundberg AL, et al. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1348-56. doi: 10.1007/s00259-003-1308-9. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937952
Survival was investigated using both a clonogenic survival assay and a cell growth assay. Combined gefitinib and 211At-EGF treatment reduced the survival of U343 cells 3.5-fold compared with 211At-EGF alone. ...
Survival was investigated using both a clonogenic survival assay and a cell growth assay. Combined gefitinib and 211At-EGF tre …
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.
Sundberg AL, Orlova A, Bruskin A, Gedda L, Carlsson J, Blomquist E, Lundqvist H, Tolmachev V. Sundberg AL, et al. Cancer Biother Radiopharm. 2003 Aug;18(4):643-54. doi: 10.1089/108497803322287736. Cancer Biother Radiopharm. 2003. PMID: 14503960
Hence, the EGFR can be used as target structure for a specific targeting of glioblastomas. Both radiolabeled anti-EGFR antibodies and the natural ligand EGF are candidate agents for targeting. ...The results indicate that [(111)In]benzyl-DTPA-hEGF is a potential can …
Hence, the EGFR can be used as target structure for a specific targeting of glioblastomas. Both radiolabeled anti-EGFR antibodies and …
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
Sundberg AL, Gedda L, Orlova A, Bruskin A, Blomquist E, Carlsson J, Tolmachev V. Sundberg AL, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):195-204. doi: 10.1089/108497804323071977. Cancer Biother Radiopharm. 2004. PMID: 15186600
As a target, overexpressed epidermal growth factor receptors (EGFR) may be used. A natural ligand to EGFR, the epidermal growth factor (EGF) is an attractive targeting agent due to its low molecular weight (6 kDa) and high affinity for EGFR. 177Lu (T(1/2) = 6.7 days …
As a target, overexpressed epidermal growth factor receptors (EGFR) may be used. A natural ligand to EGFR, the epidermal growt …
Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
Tolmachev V, Orlova A, Wei Q, Bruskin A, Carlsson J, Gedda L. Tolmachev V, et al. Cancer Biother Radiopharm. 2004 Aug;19(4):491-501. doi: 10.1089/cbr.2004.19.491. Cancer Biother Radiopharm. 2004. PMID: 15453964
Natural ligand of EGFR, epidermal growth factor (EGF) is a small 53-amino-acid protein. Low molecular weight of EGF may enable better intratumoral penetration in comparison to antibodies. [111In]DTPA-EGF was proposed for the targeting of glioblastoma and breast cancer, and …
Natural ligand of EGFR, epidermal growth factor (EGF) is a small 53-amino-acid protein. Low molecular weight of EGF may enable better …
Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker.
Cheng J, Persson M, Tolmachev V, Siavaev I, Orlova A, Kairemo K, Anniko M. Cheng J, et al. Acta Otolaryngol. 2004 Nov;124(9):1078-85. doi: 10.1080/00016480410017891. Acta Otolaryngol. 2004. PMID: 15513553
Radioimmunotargeting might be a possible treatment modality in this case. The nuclear properties of 131I make it a suitable isotope for treatment of minimal residual disease and small metastases, but the conventional radioiodine label has poor cellular retention and …
Radioimmunotargeting might be a possible treatment modality in this case. The nuclear properties of 131I make it a suitable is …
481 results
Jump to page
Feedback